Literature DB >> 11181396

Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents.

P G Hoggard1, J Lloyd, S H Khoo, M G Barry, L Dann, S E Gibbons, E G Wilkins, C Loveday, D J Back.   

Abstract

We sought to determine whether the intracellular activation of zidovudine (ZDV) varied over time and with previous antiretroviral exposure in human immunodeficiency virus-infected individuals and to examine whether there is an association between virological responses and intracellular phosphorylation. A total of 23 patients (12 treatment naïve, 11 previously treated with ZDV) who commenced ZDV as part of dual nucleoside therapy were prospectively monitored for 12 months or until withdrawal from the study. No association was observed between virological responses at 2 weeks and 3 months and ZDV phosphorylation. The mean intracellular concentrations of ZDV mono-, di-, and triphosphates did not change significantly over time or with previous ZDV exposure. The rate of formation of total ZDV phosphates was increased in patients with CD4 counts <100 cells/mm(3). Previous reports from in vitro cell culture experiments or cross-sectional cohort studies suggesting alterations of ZDV phosphorylation over time are not confirmed by this longitudinal study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181396      PMCID: PMC90409          DOI: 10.1128/AAC.35.3.976-980.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites.

Authors:  M G Barry; S H Khoo; G J Veal; P G Hoggard; S E Gibbons; E G Wilkins; O Williams; A M Breckenridge; D J Back
Journal:  AIDS       Date:  1996-10       Impact factor: 4.177

2.  Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive thai patients and healthy volunteers.

Authors:  Y Wattanagoon; K Na Bangchang; P G Hoggard; S H Khoo; S E Gibbons; D Phiboonbhanakit; J Karbwang; D J Back
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 3.  Determinants of virological response to antiretroviral therapy: implications for long-term strategies.

Authors:  S G Deeks
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

4.  Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.

Authors:  W Y Gao; D G Johns; H Mitsuya
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

5.  Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism.

Authors:  B Jacobsson; S Britton; Q He; A Karlsson; S Eriksson
Journal:  AIDS Res Hum Retroviruses       Date:  1995-07       Impact factor: 2.205

6.  Concentrations of phosphorylated zidovudine (ZDV) in patient leukocytes do not correlate with ZDV dose or plasma concentrations.

Authors:  B N Stretcher; A J Pesce; J A Murray; P E Hurtubise; W H Vine; P T Frame
Journal:  Ther Drug Monit       Date:  1991-07       Impact factor: 3.681

7.  Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.

Authors:  B N Stretcher; A J Pesce; P T Frame; K A Greenberg; D S Stein
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

8.  Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection.

Authors:  V I Avramis; R Kwock; M M Solorzano; E Gomperts
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-12

9.  Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene.

Authors:  S Wu; X Liu; M M Solorzano; R Kwock; V I Avramis
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-01-01

10.  Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers.

Authors:  M Barry; M Wild; G Veal; D Back; A Breckenridge; R Fox; N Beeching; F Nye; P Carey; D Timmins
Journal:  AIDS       Date:  1994-08       Impact factor: 4.177

View more
  8 in total

1.  Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.

Authors:  Stephen Kewn; Patrick G Hoggard; Sean D Sales; Kevin Jones; Bridget Maher; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients.

Authors:  C Bazzoli; H Bénech; E Rey; S Retout; D Salmon; X Duval; J M Tréluyer; F Mentré
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.

Authors:  M Rodriguez-Torres; F J Torriani; V Soriano; M J Borucki; E Lissen; M Sulkowski; D Dieterich; K Wang; J-M Gries; P G Hoggard; D Back
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 4.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

5.  Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

Authors:  Phumla Z Sinxadi; Jan-Stefan van der Walt; Helen M McIlleron; Motasim Badri; Peter J Smith; Joel A Dave; Naomi S Levitt; Gary Maartens
Journal:  AIDS Res Ther       Date:  2010-07-14       Impact factor: 2.250

6.  Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.

Authors:  Stephen Kewn; Laurene H Wang; Patrick G Hoggard; Franck Rousseau; Robert Hart; John P MacNeela; Saye H Khoo; David J Back
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Nancy M Kivel; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

8.  Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.

Authors:  Julie B Dumond; Camden P Bay; Julie A E Nelson; Angel Davalos; Andrew Edmonds; Kristina De Paris; Craig Sykes; Kathryn Anastos; Roopali Sharma; Seble Kassaye; Bani Tamraz; Audrey L French; Stephen Gange; Ighovwerha Ofotokun; Margaret A Fischl; David E Vance; Adaora A Adimora
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.